Single Gene Disorders Resource Network, 41401-41406 [05-14166]

Agencies

• Centers for Disease Control and Prevention
• DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 70, Number 137 (Tuesday, July 19, 2005)]
[Notices]
[Pages 41401-41406]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-14166]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Single Gene Disorders Resource Network

    Announcement Type: New.
    Funding Opportunity Number: AA092.
    Catalog of Federal Domestic Assistance Number: 93.283.
    Key Dates:
    Letter of Intent (LOI) Deadline: July 29, 2005.
    Application Deadline: August 18, 2005.

I. Funding Opportunity Description

    Authority: This program is authorized under Sections 301, 311 
and 317(C) of the Public Health Service Act [42 U.S.C. 241, 243, and 
247b-4 as amended].

    Background: There are over 6000 known single gene disorders, 
including over 1650 with identified genes. Single gene disorders occur 
in about one in 300 births, and account for 13 percent of in-patients 
in pediatric hospital and three to five percent of pediatric deaths. 
The National Center on Birth Defects and Developmental Disabilities 
(NCBDDD) seeks to ensure the optimal outcome of people with disabling 
or potential disabling pediatric single gene conditions and their 
families, by developing surveillance systems that meet challenges of 
single gene disorders, improving screening and diagnosis, and improving 
services to patients and families. Genetic disorders raise different 
issues for health care providers and families than do non-genetic 
disorders because genetic disorders have implications for other family 
members, and raise psychosocial issues (such as guilt, blame and 
stigmatization). Lessons learned from public health activities in 
single gene disorders can be applied to complex disorders as their 
etiologies become elucidated.
    This cooperative agreement will fund the development of a national 
resource network for single gene disorders. Initial funding will 
support projects related to Duchenne and Becker Muscular Dystrophy 
(DBMD) and Fragile X syndrome (FXS). The proposed National Network will 
have the capacity to expand to other single gene disorders.
    Purpose: The purpose of the program is to develop, implement, and 
evaluate a Network for Single Gene Disorders, focusing specifically on 
DBMD and FXS. This program addresses the ``Healthy People 2010'' focus 
areas of Disability and Secondary Conditions; Mental Health and Mental 
Health Disorders; and Maternal, Infant, and Child Health.''.
    Measurable outcomes of the program will be in alignment with one 
(or more) of the following performance goal(s) for the National Center 
on Birth Defects and Developmental Disabilities (NCBDDD): Prevent birth 
defects and developmental disabilities, and improve the health and 
quality of life of Americans with disabilities.
    This announcement is only for non-research activities supported by 
CDC/ATSDR. If research is proposed, the application will not be 
reviewed. For the definition of research, please see the CDC Web site 
at the following Internet address: https://www.cdc.gov/od/ads/
opspoll1.htm.
    Activities:
    Applicants may apply for funding under part A and/or part B. Please 
note that if applicants choose to apply for both part A and part B, 
applicants may submit consolidated applications addressing the 
requirements of both part A and part B under one application.
    Awardee activities for part A of this program are as follows:
     Increase access to accurate and scientifically valid 
information on the etiology, diagnosis, and treatment of DBMD for end 
users including families, educators, health professionals, allied 
health caregivers, and the general public. The awardee will 
specifically assemble and/or develop informational materials that: (1) 
Reflect expert opinion, evidence-based knowledge and current clinical 
practice, and (2) respond to the needs of individuals and families 
affected by DBMD. These informational materials will be disseminated to 
the target populations.
     Assess current educational and outreach materials related 
to DBMD targeted at families with DBMD and the general public. Develop 
and/or modify, implement and evaluate educational materials for 
families with DBMD and the general public, including information on the 
etiology, clinical course, treatment options, and available services 
(including services supported by Health Resources and Services 
Administration, the Administration for Children and Families/
Administration on Developmental Disabilities, and other DHHS-supported 
efforts that target families of children with disabilities). Content of 
materials includes issues specific to single gene disorders, such as 
genetic counseling.
     Assess current educational and outreach materials related 
to DBMD targeted at health care providers. Develop and/or modify, 
implement and evaluate educational materials for providers and 
students, focusing on recognition, diagnosis, referral and treatment. 
Content of materials includes current diagnostic and treatment 
standards or guidelines; and issues specific to single gene disorders, 
such as genetic counseling.
     Disseminate the information on DBMD widely within the 
targeted group including families, educators, health professionals, 
allied health caregivers, and the general public. This may be new or 
existing materials in a variety of formats including written, video, 
CD, and World Wide Web. Ensure the dissemination plan for the materials 
is developed, methods for reaching under-served and minority 
communities are described and justified; and accurate information about 
diagnosis and treatment of DBMD is available to various stakeholders, 
i.e., practitioners, families, teachers, and other caregivers.
     Coordinate educational activities with other community-
based and community-wide providers and organizations that offer 
services or direct education messages to U.S. residents that have DBMD 
and their providers.
     Hire and train staff as necessary to implement education 
and outreach activities for DBMD.
     Increase opportunities for regular and ongoing DBMD 
training and education available to persons within the targeted 
audiences.
     Identify core competencies about DBMD for medical and 
allied health students.
     Evaluate the core competencies for appropriateness and 
validity based on needs of the audiences and on scientific research.
     Develop methods to ensure that materials and resources for 
DBMD education and training are easily accessible.
     Coordinate activities with other awardees.
    Awardee activities for part B of this program are as follows:
     Increase access to accurate and scientifically valid 
information on the etiology, diagnosis, and treatment of FXS for end 
users including health professionals, allied health caregivers, and 
students. The awardee will specifically assemble and/or develop

[[Page 41402]]

informational materials that: (1) reflect expert opinion, evidence-
based knowledge and current clinical practice; and (2) respond to the 
needs of individuals and families affected by FXS. These informational 
materials will be disseminated to the target populations.
     Assess current educational and outreach materials related 
to FXS targeted at health care providers. Develop and/or modify, 
implement and evaluate educational materials for providers and 
students, focusing on recognition, diagnosis, referral and treatment. 
Content of materials includes current diagnostic and treatment 
standards or guidelines; and issues specific to single gene disorders, 
such as genetic counseling.
     Disseminate the information on FXS widely within the 
targeted group including health professionals, allied health 
caregivers, and students. This may be new or existing materials in a 
variety of formats including written, video, CD and World Wide Web. 
Ensure the dissemination plan for the materials is developed, methods 
for reaching under-served and minority communities are described and 
justified, and accurate information about diagnosis and treatment of 
FXS is available to various stakeholders, i.e., practitioners, 
teachers, and other caregivers.
     Coordinate educational activities with other community-
based and community-wide providers and organizations that offer 
services or direct education messages to U.S. residents who have FXS 
and their providers.
     Hire and train staff as necessary to implement education 
and outreach activities for FXS.
     Increase opportunities for regular and ongoing FXS 
training and education available to persons within the targeted 
audiences.
     Identify core competencies about FXS for medical and 
allied health students.
     Evaluate the core competencies for appropriateness and 
validity based on needs of the audiences and on scientific research.
     Develop methods to ensure that materials and resources for 
FXS education and training are easily accessible.
     Coordinate activities with other awardees.
    In a cooperative agreement, CDC staff is substantially involved in 
the program activities, above and beyond routine grant monitoring. CDC 
Activities for this program are as follows:
     Assist recipients in monitoring program evaluation/
performance; setting and meeting objectives; implementing methods, and 
complying with cooperative agreement requirements and other funding 
issues, through various methods including telephone consultation, site 
visits, and site visit reports.
     Assist recipients in coordination of activities where 
possible.
     Assist recipients in coordination of activities with those 
of related partner organizations, including HRSA maternal and child 
health, Community Health Centers and OPA family planning.
     Assist recipients in developing and maintaining working 
relationships with stakeholder organizations.
     Provide technical assistance in assessing and prioritizing 
training and educational needs and in planning, implementing, and 
evaluating training and educational activities.
     Provide technical assistance in developing and evaluating 
innovative curriculum approaches, instructional strategies, and 
materials.

II. Award Information

Part A: Duchenne and Becker Muscular Dystrophy

    Type of Award: Cooperative Agreement. CDC involvement in this 
program is listed in the Activities Section above.
    Fiscal Year Funds: 2005.
    Approximate Total Funding: $600,000 (This amount is an estimate, 
and is subject to availability of funds.)
    Approximate Number of Awards: One.
    Approximate Average Award: $600,000 (This amount is for the first 
12-month budget period, and includes both direct and indirect costs).
    Floor of Award Range: $500,000.
    Ceiling of Award Range: $600,000 (This ceiling is for the first 12-
month budget period.)
    Anticipated Award Date: August 30, 2005.
    Budget Period Length: 12 months.
    Project Period Length: Five years.

Part B: Fragile X Syndrome

    Type of Award: Cooperative Agreement. CDC involvement in this 
program is listed in the Activities Section above.
    Fiscal Year Funds: 2005.
    Approximate Total Funding: $250,000 (This amount is an estimate, 
and is subject to availability of funds.)
    Approximate Number of Awards: One.
    Approximate Average Award: $250,000 (This amount is for the first 
12-month budget period, and includes both direct and indirect costs).
    Floor of Award Range: $200,000.
    Ceiling of Award Range: $250,000 (This ceiling is for the first 12-
month budget period.)
    Anticipated Award Date: August 30, 2005.
    Budget Period Length: 12 months.
    Project Period Length: Five years. Throughout the project period, 
CDC's commitment to continuation of awards will be conditioned on the 
availability of funds, evidence of satisfactory progress by the 
recipient (as documented in required reports), and the determination 
that continued funding is in the best interest of the Federal 
Government.

III. Eligibility Information

III.1. Eligible Applicants

    Eligible applicants that can apply for this funding opportunity are 
listed below:
     Public nonprofit organizations
     Private nonprofit organizations
     For profit organizations
     Small, minority, women-owned businesses
     Universities
     Colleges
     Research institutions
     Hospitals
     Community-based organizations
     Faith-based organizations
     Federally recognized Indian tribal governments
     Indian tribes
     Indian tribal organizations
     State and local governments or their Bona Fide Agents 
(this includes the District of Columbia, the Commonwealth of Puerto 
Rico, the Virgin Islands, the Commonwealth of the Northern Marianna 
Islands, American Samoa, Guam, the Federated States of Micronesia, the 
Republic of the Marshall Islands, and the Republic of Palau)
     Political subdivisions of States (in consultation with 
States)
    A Bona Fide Agent is an agency/organization identified by the state 
as eligible to submit an application under the state eligibility in 
lieu of a state application. If applying as a bona fide agent of a 
State or local government, a letter from the State or local government 
as documentation of the status is required. Place this documentation 
behind the first page of the application form.

III.2. Cost Sharing or Matching

    Matching funds are not required for this program.

III.3. Other

    A successful applicant must be an organization with a national 
scope of operations.

[[Page 41403]]

    If a funding amount greater than the ceiling of the award range is 
requested, the application will be considered non-responsive and will 
not be entered into the review process. The applicant will be notified 
that the application did not meet the submission requirements.
    Special Requirements:
    If the application is incomplete or non-responsive to the special 
requirements listed in this section, it will not be entered into the 
review process. The applicant will be notified that the application did 
not meet submission requirements.
     Late applications will be considered non-responsive. See 
section ``IV.3. Submission Dates and Times'' for more information on 
deadlines.

     Note: Title 2 of the United States Code 
Section 1611 states that an organization described in Section 
501(c)(4) of the Internal Revenue Code that engages in lobbying 
activities is not eligible to receive Federal funds constituting an 
award, grant, or loan.

     Assistance will be provided only to a well-established 
non-profit organization with experience in: (1) Assisting parents and 
families of people with genetic disorders; (2) conducting a national 
medical and public education agenda that focuses on producing valuable 
literature for families with genetic disorders, health care providers, 
and allied health caregivers; and (3) communicating research findings 
effectively to national, regional, state and local level media outlets 
in coordination with partners.

IV. Application and Submission Information

IV.1 Address to Request Application Package

    To apply for this funding opportunity use application form PHS 
5161-1.
    Electronic Submission:
    CDC strongly encourages the applicant to submit the application 
electronically by utilizing the forms and instructions posted for this 
announcement on https://www.Grants.gov, the official Federal agency wide 
E-grant Web site. Only applicants who apply on-line are permitted to 
forego paper copy submission of all application forms. Application 
forms and instructions are available on the CDC web site, at the 
following Internet address: https://www.cdc.gov/od/pgo/forminfo.htm.
    Paper Submission:
    Application forms and instructions are available on the CDC Web 
site, at the following Internet address: https://www.cdc.gov/od/pgo/
forminfo.htm.
    If access to the Internet is not available, or if there is 
difficulty accessing the forms on-line, contact the CDC Procurement and 
Grants Office Technical Information Management Section (PGO-TIM) staff 
at: 770-488-2700. Application forms can be mailed.

IV.2. Content and Form of Application Submission:

    Your LOI must be written in the following format:
     Maximum number of pages: Two
     Font size: 12-point unreduced
     Single spaced
     Paper size: 8.5 by 11 inches
     Page margin size: One inch
     Printed only on one side of the page
     Written in English, avoid jargon
    Your LOI must contain the following information:
     Name
     Address
     Telephone number
     Principal Investigator
     Number and title of this program announcement
     Intent to apply under part A and/or part B of this 
announcement
     Names of other key personnel
     Designations of collaborating institutions and entities
     Recruitment approach
     Expected Outcomes
    Application: A project narrative must be submitted with the 
application forms. The narrative must be submitted in the following 
format:
     Maximum number of pages: 25 for part A or part B, 30 for 
parts A and B combined. If your narrative exceeds the page limit, only 
the first pages which are within the page limit will be reviewed.
     Font size: 12 point unreduced
     Double spaced
     Paper size: 8.5 by 11 inches
     Page margin size: One inch
     Printed only on one side of page
     Held together only by rubber bands or metal clips; not 
bound in any other way.
    The narrative should address activities to be conducted over the 
entire project period, and must include the following items in the 
order listed:
     A demonstrated understanding of the problem of single gene 
disorders including DBMD and/or FXS and the justification of the need 
for establishment of the Single Gene Disorders Resource Network.
     A description of the goals and specific objectives of the 
project in time-framed, measurable terms.
     A detailed plan describing the approach to be taken in 
implementing the project and the methods by which the objectives will 
be achieved and evaluated, including their sequence. A comprehensive 
evaluation plan must be outlined.
     A description of the specific products to be developed 
and/or disseminated through the project.
     A description of the cooperative agreement's principal 
investigator's role and responsibilities.
     A description of all the project staff, regardless of 
their funding source. It should include their title, qualifications, 
experience, percentage of time each will devote to the project, as well 
as that portion of their salary to be paid by the cooperative 
agreement.
     A description of relationships with voluntary health 
organizations and other organizations that offer services or direct 
education messages to U.S. residents that have single gene disorders 
including DBMD and/or FXS and their providers dedicated; and a 
description of a plan to involve these organizations in the 
development, implementation and evaluation of this project.
     A detailed first year's budget for the cooperative 
agreement with future annual projections. Awards will be made for a 
project period of up to five years. (Budget justification is not 
included in narrative page limit).
    Additional information may be included in the application 
appendices. The appendices will not be counted toward the narrative 
page limit. This additional information includes:
     Curricula Vitae
     Letters of Support
    The agency or organization is required to have a Dun and Bradstreet 
Data Universal Numbering System (DUNS) number to apply for a grant or 
cooperative agreement from the Federal government. The DUNS number is a 
nine-digit identification number, which uniquely identifies business 
entities. Obtaining a DUNS number is easy and there is no charge. To 
obtain a DUNS number, access https://www.dunandbradstreet.com or call 1-
866-705-5711.
    For more information, see the CDC Web site at: https://www.cdc.gov/
od/pgo/funding/grantmain.htm. If the application form does not have a 
DUNS number field, please write the DUNS number at the top of the first 
page of the application, and/or include the DUNS number in the 
application cover letter.
    Additional requirements that may require submittal of additional 
documentation with the application are listed in section ``VI.2. 
Administrative and National Policy Requirements.''

IV.3. Submission Dates and Times

    Letter of Intent (LOI) Deadline Date: July 29, 2005.
    CDC requests that you send a LOI if you intend to apply for this 
program. The LOI will be used to gauge the level

[[Page 41404]]

of interest in this program, and to allow CDC to plan the application 
review.
    Application Deadline Date: August 18, 2005.
    Explanation of Deadlines: Applications must be received in the CDC 
Procurement and Grants Office by 4 p.m. eastern time on the deadline 
date.
    Applications may be submitted electronically at https://
www.grants.gov. Applications completed on-line through Grants.gov are 
considered formally submitted when the applicant organization's 
Authorizing Official electronically submits the application to https://
www.grants.gov. Electronic applications will be considered as having 
met the deadline if the application has been submitted electronically 
by the applicant organization's Authorizing Official to Grants.gov on 
or before the deadline date and time.
    If submittal of the application is done electronically through 
Grants.gov (https://www.grants.gov), the application will be 
electronically time/date stamped, which will serve as receipt of 
submission. Applicants will receive an e-mail notice of receipt when 
CDC receives the application.
    If submittal of the application is by the United States Postal 
Service or commercial delivery service, the applicant must ensure that 
the carrier will be able to guarantee delivery by the closing date and 
time. If CDC receives the submission after the closing date due to: (1) 
carrier error, when the carrier accepted the package with a guarantee 
for delivery by the closing date and time, or (2) significant weather 
delays or natural disasters, the applicant will be given the 
opportunity to submit documentation of the carrier's guarantee. If the 
documentation verifies a carrier problem, CDC will consider the 
submission as having been received by the deadline.
    If a hard copy application is submitted, CDC will not notify the 
applicant upon receipt of the submission. If questions arise on the 
receipt of the application, the applicant should first contact the 
carrier. If the applicant still has questions, contact the PGO-TIM 
staff at (770) 488-2700. The applicant should wait two to three days 
after the submission deadline before calling. This will allow time for 
submissions to be processed and logged.
    This announcement is the definitive guide on application content, 
submission address, and deadline. It supersedes information provided in 
the application instructions. If the submission does not meet the 
deadline above, it will not be eligible for review, and will be 
discarded. The applicant will be notified the application did not meet 
the submission requirements.

IV.4. Intergovernmental Review of Applications

    Executive Order 12372 does not apply to this program.

IV.5. Funding Restrictions

    Restrictions, which must be taken into account while writing your 
budget, are as follows:
     Funds may not be used for research.
     Reimbursement of pre-award costs is not allowed.
    If requesting indirect costs in the budget, a copy of the indirect 
cost rate agreement is required. If the indirect cost rate is a 
provisional rate, the agreement should be less than 12 months of age.
    Guidance for completing your budget can be found on the CDC Web 
site, at the following Internet address: https://www.cdc.gov/od/pgo/
funding/budgetguide.htm.

IV.6. Other Submission Requirements

    LOI Submission Address: Submit your LOI by express mail, delivery 
service, fax, or e-mail to: Michael Brown, Project Officer, Centers for 
Disease Control and Prevention (CDC), National Center on Birth Defects 
and Developmental Disabilities, Division of Human Development and 
Disability, 1600 Clifton Road NE, Mailstop E-88, Atlanta, GA 30333; 
Telephone: 404-498-3006; E-mail: MABrown@cdc.gov.
    Application Submission Address:
    Electronic Submission:
    CDC strongly encourages applicants to submit applications 
electronically at https://www.Grants.gov. The application package can be 
downloaded from https://www.Grants.gov. Applicants are able to complete 
it off-line, and then upload and submit the application via the 
Grants.gov Web site. E-mail submissions will not be accepted. If the 
applicant has technical difficulties in Grants.gov, costumer service 
can be reached by E-mail at https://www.grants.gov/CustomerSupport or by 
phone at 1-800-518-4726 (1-800-518-GRANTS). The Customer Support Center 
is open from 7 a.m. to 9 p.m. eastern time, Monday through Friday.
    CDC recommends that submittal of the application to Grants.gov 
should be early to resolve any unanticipated difficulties prior to the 
deadline. Applicants may also submit a back-up paper submission of the 
application. Any such paper submission must be received in accordance 
with the requirements for timely submission detailed in Section IV.3. 
of the grant announcement. The paper submission must be clearly marked: 
``BACK-UP FOR ELECTRONIC SUBMISSION.'' The paper submission must 
conform to all requirements for non-electronic submissions. If both 
electronic and back-up paper submissions are received by the deadline, 
the electronic version will be considered the official submission.
    It is strongly recommended that the applicant submit the grant 
application using Microsoft Office products (e.g., Microsoft Word, 
Microsoft Excel, etc.). If the applicant does not have access to 
Microsoft Office products, a PDF file may be submitted. Directions for 
creating PDF files can be found on the Grants.gov Web site. Use of file 
formats other than Microsoft Office or PDF may result in the file being 
unreadable by staff.
    OR
    Paper Submission:
    Applicants should submit the original and two hard copies of the 
application by mail or express delivery service to: Technical 
Information Management [RFA AA092], CDC Procurement and Grants 
Office, 2920 Brandywine Road, Atlanta, GA 30341.

V. Application Review Information

V.1. Criteria

    Applicants are required to provide measures of effectiveness that 
will demonstrate the accomplishment of the various identified 
objectives of the cooperative agreement. Measures of effectiveness must 
relate to the performance goals stated in the ``Purpose'' section of 
this announcement. Measures must be objective and quantitative, and 
must measure the intended outcome. These measures of effectiveness must 
be submitted with the application and will be an element of evaluation.
    The application will be evaluated against the following criteria:
    1. Capacity to Conduct Project Activities and Begin Project 
Operations in a Timely Fashion (30%)
    The extent to which the applicant has provided information to 
support its ability to conduct the activities of the cooperative 
agreement, including documentation of previous relevant experience; 
documentation of institutional support for the project; demonstrated 
ability to identify qualified personnel to fill key positions and begin 
project activities in a timely fashion; and the ability to identify 
adequate office space for the project as well as facilities for 
conducting training/educational sessions. The extent to which the 
organization has

[[Page 41405]]

with experience in: (1) Assisting parents and families of people with 
genetic disorders (2) conducting a national medical and public 
education agenda that focuses on producing valuable literature for 
families with genetic disorders, health care providers, and allied 
health caregivers (3) communicating research findings effectively to 
national, regional, state and local level media outlets in coordination 
with partners.
    2. Applicant's Understanding of the Problem (20%)
    The extent to which the applicant demonstrates an understanding of 
the resource needs related to single gene disorders, including DBMD 
and/or FXS, and the importance of educating medical and allied health 
students and practitioners about these conditions.
    3. Goals and Objectives (20%)
    The extent to which the project goals are clearly stated and the 
objectives are specific, measurable, and time-phased. Also, the extent 
to which a plan is presented for evaluating the objectives.
    4. Collaboration with Voluntary Health and Related Organizations 
(15%)
    The extent to which the applicant has provided a full and 
comprehensive description of partnerships with voluntary health 
organizations and other organizations that offer services or direct 
education messages to U.S. residents that have genetic disorders 
including DBMD and/or FXS and their providers; and a description of a 
plan to involve these organizations in the development, implementation 
and evaluation of this project.
    5. Plan of Operation (15%)
    The extent to which the applicant has provided a full and 
comprehensive description of the project they propose to undertake and 
a plan for how it will be accomplished. The applicant must also 
describe the methods by which the objectives will be achieved and 
evaluated.
    6. Budget Justification and Adequacy of Facilities (not scored)
    The budget will be evaluated for the extent to which it is 
reasonable, clearly justified, and consistent with the intended use of 
the cooperative agreement funds. The applicant shall describe and 
indicate the availability of facilities and equipment necessary to 
carry out this project.
    7. Human Subjects Review (not scored)
    Does the application adequately address the requirements of Title 
45 CFR Part 46 for the protection of human subjects?

V.2. Review and Selection Process

    Applications will be reviewed for completeness by the Procurement 
and Grants Office (PGO) staff, and for responsiveness by the National 
Center on Birth Defects and Developmental Disabilities (NCBDDD). 
Incomplete applications and applications that are non-responsive to the 
eligibility criteria will not advance through the review process. 
Applicants will be notified that their application did not meet 
submission requirements.
    An objective review panel will evaluate complete and responsive 
applications according to the criteria listed in the ``V.1. Criteria'' 
section above. The objective review panel will consist of CDC employees 
outside of the funding division, who will be randomly assigned 
applications to review and score. Applications will be funded in order 
by score and rank determined by the review panel. Applicants that apply 
under both part A and part B will receive separate scores for each 
part. CDC will provide justification for any decision to fund out of 
rank order. Subsequent to the formal review of all competitive 
applications, a second level of review will be conducted by senior CDC 
program staff. This review will not revisit the scientific merit of the 
applications, but will evaluate the overall budget implications of the 
applications against funding ceilings; they may not make 
recommendations as to the final ordering of the top ranked applications 
for part A and part B, and they may not actually change the ranking 
order (or scores). It is possible that the second level of review may 
recommend funding the highest ranked proposal under part A (or part B) 
and also funding that same organization under its application for the 
other part of the announcement. That could occur in the event that an 
organization with the highest ranking in one part ranks among the 
highest three applicants in the other part. This would be done to take 
into account economies of scale and establish the capacity to conduct 
non-redundant programs to best meet the purposes of this announcement. 
In such a case, the total approved budget may be less than the sum of 
the two applications due to staff time commitment duplications and 
other considerations.

V.3. Anticipated Announcement and Award Dates

    August 31,2005 for a September 30, 2005 project start date.

VI. Award Administration Information

VI.1. Award Notices

    Successful applicants will receive a Notice of Award (NoA) from the 
CDC Procurement and Grants Office. The NoA shall be the only binding, 
authorizing document between the recipient and CDC. The NGA will be 
signed by an authorized Grants Management Officer, and mailed to the 
recipient fiscal officer identified in the application.
    Unsuccessful applicants will receive notification of the results of 
the application review by mail.

VI.2. Administrative and National Policy Requirements

    Successful applicants must comply with the administrative 
requirements outlined in 45 CFR part 74 and part 92 as Appropriate. The 
following additional requirements apply to this project:
     AR-9--Paperwork Reduction Act Requirements
     AR-10--Smoke-Free Workplace Requirements
     AR-11--Healthy People 2010
     AR-12--Lobbying Restrictions
    Additional information on these requirements can be found on the 
CDC Web site at the following Internet address: https://www.cdc.gov/od/
pgo/funding/ARs.htm.
    For more information on the Code of Federal Regulations, see the 
National Archives and Records Administration at the following Internet 
address: https://www.access.gpo.gov/nara/cfr/cfr-table-search.html.
    An additional Certifications form from the PHS5161-1 application 
needs to be included in the Grants.gov electronic submission only. 
Applicants should refer to https://www.cdc.gov/od/pgo/funding/PHS5161-1-
Certificates.pdf. Once the applicant has filled out the form, it should 
be attached to the Grants.gov submission as Other Attachments Form.

VI.3. Reporting Requirements

    The applicant must provide CDC with an original, plus two hard 
copies of the following reports:
    1. Interim progress report, due no less than 90 days before the end 
of the budget period. The progress report will serve as your non-
competing continuation application, and must contain the following 
elements:
    a. Current Budget Period Activities Objectives.
    b. Current Budget Period Financial Progress.
    c. New Budget Period Program Proposed Activity Objectives.

[[Page 41406]]

    d. Budget.
    e. Measures of Effectiveness.
    f. Additional Requested Information.
    2. Financial status report, no more than 90 days after the end of 
the budget period.
    3. Final financial and performance reports, no more than 90 days 
after the end of the project period.
    These reports must be mailed to the Grants Management or Contract 
Specialist listed in the ``Agency Contacts'' section of this 
announcement.

VII. Agency Contacts

    We encourage inquiries concerning this announcement.
    For general questions, contact: Technical Information Management 
Section, CDC Procurement and Grants Office, 2920 Brandywine Road, 
Atlanta, GA 30341; Telephone: 770-488-2700.
    For program technical assistance, contact: Michael Brown, Project 
Officer, Centers for Disease Control and Prevention (CDC), National 
Center on Birth Defects and Developmental Disabilities, Division of 
Human Development and Disability, 1600 Clifton Road NE., Mailstop E-88, 
Atlanta, GA 30333; Telephone: 404-498-3006; E-mail: MABrown@cdc.gov.
    For financial, grants management, or budget assistance, contact: 
Mildred Garner, Grants Management Officer, CDC Procurement and Grants 
Office, 2920 Brandywine Road, Atlanta, GA 30341; Telephone: (770) 488-
2745; E-mail: mqg4@cdc.gov.

VIII. Other Information

    This and other CDC funding opportunity announcements can be found 
on the CDC Web site, Internet address: https://www.cdc.gov. Click on 
``Funding'' then ``Grants and Cooperative Agreements.''

    Dated: July 13, 2005.
Alan A. Kotch,
Acting Director, Procurement and Grants Office, Centers for Disease 
Control and Prevention.
[FR Doc. 05-14166 Filed 7-18-05; 8:45 am]
BILLING CODE 4163-18-P